Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-in-human study of oral KAND567 in healthy volunteers
NL-OMON44294Phase 1Active, not recruiting
- Sponsor
- Kancera
- Start
- May 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in multiple sclerosis (MS) comparing KAND567 with Placebo (2 arms). Primary endpoint: Safety and tolerability. Started May 2017; status: active, not recruiting.
02
Drugs
rugocrixan
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NL-OMON44294.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON44294.